Contributions
Abstract: PB1858
Type: Publication Only
Background
The expression of FAS, TRAIL, TNFR2, DR4/5 and DR3 are dysregulated in set of hematological malignancies. As result, apoptotic process in malignant cell is blocked due to lack of membrane apoptotic receptors. It may have negative clinical significance. We wanted to investigate the most important gene among listed.
Aims
To determinate clinical significance of FAS, TRAIL, TNFR2, DR4/5 and DR3 genes in primary B-CLL.
Methods
The expression level of FAS, TRAIL, TNFR2, DR4/5 and DR3 genes was studied in 23 patients with newly diagnosed chronic lymphocytic leukemia (B-CLL) before and after RFC-therapy. Multivariate regression analysis to perform clinical significance of each gene.
Results
According to multivariate regression analysis results, among these genes the FAS expression level has most value in clinical outcome. There are two conditions of FAS activity was observed – high expression level (median 7717%), and low (373%). Patients with high expression level of FAS has I-II stage of diesis (p = 0.0205), lowest level of lymphocytes (p = 0.0016) and highest level of erythrocytes (p = 0.0159), and highest TNFR2 and TRAIL expression level (p = 0.0015 and p = 0.0053, respectively). Patients with low expression level of FAS has poorer clinical outcome (p = 0.026).
Conclusion
Highest level of FAS, TRAIL и TNFR2 is associated with sensitivity oh B-CLL cells to induction of apoptosis. Moreover, it associated with better effectiveness RFC-therapy.
Session topic: 5. Chronic lymphocytic leukemia and related disorders – Biology & Translational Research
Keyword(s): Apoptosis, B cell chronic lymphocytic leukemia, Gene expression profile
Abstract: PB1858
Type: Publication Only
Background
The expression of FAS, TRAIL, TNFR2, DR4/5 and DR3 are dysregulated in set of hematological malignancies. As result, apoptotic process in malignant cell is blocked due to lack of membrane apoptotic receptors. It may have negative clinical significance. We wanted to investigate the most important gene among listed.
Aims
To determinate clinical significance of FAS, TRAIL, TNFR2, DR4/5 and DR3 genes in primary B-CLL.
Methods
The expression level of FAS, TRAIL, TNFR2, DR4/5 and DR3 genes was studied in 23 patients with newly diagnosed chronic lymphocytic leukemia (B-CLL) before and after RFC-therapy. Multivariate regression analysis to perform clinical significance of each gene.
Results
According to multivariate regression analysis results, among these genes the FAS expression level has most value in clinical outcome. There are two conditions of FAS activity was observed – high expression level (median 7717%), and low (373%). Patients with high expression level of FAS has I-II stage of diesis (p = 0.0205), lowest level of lymphocytes (p = 0.0016) and highest level of erythrocytes (p = 0.0159), and highest TNFR2 and TRAIL expression level (p = 0.0015 and p = 0.0053, respectively). Patients with low expression level of FAS has poorer clinical outcome (p = 0.026).
Conclusion
Highest level of FAS, TRAIL и TNFR2 is associated with sensitivity oh B-CLL cells to induction of apoptosis. Moreover, it associated with better effectiveness RFC-therapy.
Session topic: 5. Chronic lymphocytic leukemia and related disorders – Biology & Translational Research
Keyword(s): Apoptosis, B cell chronic lymphocytic leukemia, Gene expression profile